We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed Launches AirFit F30i CPAP Mask, Widens Client Base
Read MoreHide Full Article
ResMed Inc. (RMD - Free Report) launched AirFit F30i, which is its first tube-up, full-face continuous positive airway pressure (CPAP) mask. With the launch, the company has completed its full-face mask portfolio in the market.
With the launch, the full-face CPAP users will now have an option of choosing among the type of connection (tube-up or tube-down), cushion styles (compact under-the-nose or traditional over-the-nose) as well as memory foam versus silicone cushion. AirFit F30i, which is being preferred by customers for features like a dependable seal and a comfortable under-the-nose fit for active sleepers, also completes ResMed’s Freedom category of tube-up masks.
Notably, other offerings like nasal tube-up AirFit N30i (released in January 2019) and nasal pillows tube-up AirFit P30i (released in April 2019) are available for users. With the latest launch, ResMed aims to strengthen its Sleep and Respiratory Care segment globally.
Significance of the Launch
The company believes that the design of AirFit F30i will make it easier for users to sleep in any position, without any soreness or irritation on the nasal bridge. Also, users need not take off the mask, while adjusting the tubing.
The company has presented favorable outcomes in a direct comparison study, where most patients preferred AirFit F30i over other full-face masks available in the market based on its design.
Industry Prospects
Per a report by MarketsAndMarkets, the global respiratory care devices market is expected to reach $31.8 billion by 2024 from $20.6 billion in 2019, witnessing a CAGR of 9.1%. Factors like rising demand for enhanced portable and compact respiratory care devices, growing demand for multimodal ventilation, and the increasing adoption of non-invasive ventilation are likely to drive the market.
Given the market potential, the launch has been timed well.
Recent Developments
ResMed launched AirFit N30, the first tube-down nasal cradle CPAP mask with a front-facing tube, in October 2019. With the launch, the company broadened its treatment option for sleep apnea.
Further, in October, ResMed entered a partnership with Cerner Corporation to help care providers make better treatment decisions, manage costs, and deliver seamless care in both health systems and home.
Price Performance
Shares of ResMed have gained 36.7% in the past year compared with the industry’s 16.2% growth.
Zacks Rank & Key Picks
Currently, the company carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) and Medtronic plc (MDT - Free Report) .
Medtronic’s long-term earnings growth rate is expected at 7.4%. It currently has a Zacks Rank #2 (Buy).
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
ResMed Launches AirFit F30i CPAP Mask, Widens Client Base
ResMed Inc. (RMD - Free Report) launched AirFit F30i, which is its first tube-up, full-face continuous positive airway pressure (CPAP) mask. With the launch, the company has completed its full-face mask portfolio in the market.
With the launch, the full-face CPAP users will now have an option of choosing among the type of connection (tube-up or tube-down), cushion styles (compact under-the-nose or traditional over-the-nose) as well as memory foam versus silicone cushion. AirFit F30i, which is being preferred by customers for features like a dependable seal and a comfortable under-the-nose fit for active sleepers, also completes ResMed’s Freedom category of tube-up masks.
Notably, other offerings like nasal tube-up AirFit N30i (released in January 2019) and nasal pillows tube-up AirFit P30i (released in April 2019) are available for users. With the latest launch, ResMed aims to strengthen its Sleep and Respiratory Care segment globally.
Significance of the Launch
The company believes that the design of AirFit F30i will make it easier for users to sleep in any position, without any soreness or irritation on the nasal bridge. Also, users need not take off the mask, while adjusting the tubing.
The company has presented favorable outcomes in a direct comparison study, where most patients preferred AirFit F30i over other full-face masks available in the market based on its design.
Industry Prospects
Per a report by MarketsAndMarkets, the global respiratory care devices market is expected to reach $31.8 billion by 2024 from $20.6 billion in 2019, witnessing a CAGR of 9.1%. Factors like rising demand for enhanced portable and compact respiratory care devices, growing demand for multimodal ventilation, and the increasing adoption of non-invasive ventilation are likely to drive the market.
Given the market potential, the launch has been timed well.
Recent Developments
ResMed launched AirFit N30, the first tube-down nasal cradle CPAP mask with a front-facing tube, in October 2019. With the launch, the company broadened its treatment option for sleep apnea.
Further, in October, ResMed entered a partnership with Cerner Corporation to help care providers make better treatment decisions, manage costs, and deliver seamless care in both health systems and home.
Price Performance
Shares of ResMed have gained 36.7% in the past year compared with the industry’s 16.2% growth.
Zacks Rank & Key Picks
Currently, the company carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) and Medtronic plc (MDT - Free Report) .
Haemonetics currently sports a Zacks Rank #1 (Strong Buy) and has a projected long-term earnings growth rate of 13.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medtronic’s long-term earnings growth rate is expected at 7.4%. It currently has a Zacks Rank #2 (Buy).
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>